FDA Reviewers Say Safety Profile on Endo's (ENDP) Aveed is 'Concerning'
Tweet
Share
E-mailGet Alerts ENDP Hot Sheet
Join SI Premium – FREE
Endo Health (Nasdaq: ENDP) is higher at the start Tuesday following reports that reviewers for the U.S. FDA said safety data on Endo's proposed testosterone injection Aveed was "concerning."
The reviewers also noted the post-injection reactions were met with severe and adverse events, though no deaths were reported. Several resuscitations and hospitalizations were noted.
A vote on the safety profile for Aveed will take place Thursday by an FDA panel.
The reviewers also noted the post-injection reactions were met with severe and adverse events, though no deaths were reported. Several resuscitations and hospitalizations were noted.
A vote on the safety profile for Aveed will take place Thursday by an FDA panel.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
- Alzamend Neuro fMRI data accepted for neuroscience conference poster
- Milestone Pharmaceuticals starts Phase 3 AFib-RVR trial for etripamil
Create E-mail Alert Related Categories
FDA, Insiders' BlogSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
